
Opinion|Videos|March 20, 2025
Navigating the Evolving First-Line Treatment Regimens in Intermediate-Stage HCC
Author(s)Richard S. Finn, MD, Amit Singal, MD
Panelists discuss how the role of systemic therapy in intermediate-stage hepatocellular carcinoma (HCC) is evolving with combinations like immunotherapy and targeted agents enhancing locoregional treatment. LEAP-012 and EMERALD-1 evaluate lenvatinib + pembrolizumab and durvalumab-based regimens with transarterial chemoembolization (TACE), respectively. Their findings may redefine treatment paradigms, improving outcomes and expanding therapeutic options.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How might the role of systemic therapy evolve in the management of intermediate-stage HCC?
- Please review and discuss the data from LEAP-012 and EMERALD-1.
- As you review data, what are the clinical implications of these results?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Daratumumab Quadruplet for Transplant-Ineligible Myeloma
2
Atebimetinib Combo Shows Compelling 1-Year OS in First-Line Pancreatic Cancer
3
FDA Grants Fast Track Designation to IBI3003 for R/R Multiple Myeloma
4
FDA Grants Breakthrough Designation for Bezuclastinib in GIST
5


















